You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Novartis AG guarantees four Novartis Capital Corporation note issuances: $500,000,000 at 4.900% due 2029; $1,500,000,000 at 5.200% due 2032; $1,750,000,000 at 5.300% due 2034; and $1,750,000,000 at 5.500% due 2037.
Novartis reported third-quarter sales growth of 4% to $14.5 billion and core operating income growth of 10% to $6 billion, and raised full-year 2026 core operating income guidance. Rapsido received FDA approval, and reaffirmed 5% to 6% constant-currency growth.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVS
this stock
Novartis AG
|
$303.12B | +16.4% | — | — | 0.2% |
|
LLY
ELI LILLY & Co
|
$1.36T | +34.3% | +44.7% | 46.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$687.89B | +38.1% | +6.0% | 43.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$521.50B | +29.1% | +8.6% | 50.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$364.26B | +40.4% | +1.3% | 152.3 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Novartis AG guarantees four Novartis Capital Corporation note issuances: $500,000,000 at 4.900% due 2029; $1,500,000,000 at 5.200% due 2032; $1,750,000,000 at 5.300% due 2034; and $1,750,000,000 at 5.500% due 2037.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVS | -1.3% | +6.6% | +6.4% | -0.2% | +16.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -3.9% | +7.7% | +5.9% | +0.0% | +5.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
